SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the 2021 Advances in Genome Biology and Technology (AGBT) meeting will feature presentations from scientists at leading research institutes and hospitals including Boston Children’s Hospital, Harvard Medical School, Tel Aviv University and the company describing their work with the Saphyr System for optical genome mapping (OGM) in psychiatric disorders and cancer. AGBT will be held virtually at https://www.agbt.org/ March 1-3. Bionano’s optical genome mapping technology will be discussed in poster presentations and plenary talks on AGBT’s main agenda. Additionally, Bionano will host a live interview with Bionano CEO Dr. Erik Holmlin and CMO Dr. Alka Chaubey conducted by Theral Timpson, Host, Producer and Co-Founder of Mendelspod as part of the official conference program. The recording of the interview will be released on Thursday, March 4 as a regular episode of Mendelspod, the leading podcast covering the genomics industry.
Below is a list of activities at AGBT 2021 featuring the use of Bionano’s optical genome mapping technology:
Plenary Talk – Session I
Monday, March 1 – 10:30A-10:50A (EST)
Research in rare pediatric psychiatric disorders (and more)
Dr. Catherine Brownstein, Assistant Professor at Boston Children’s Hospital and Harvard Medical School
Poster Presentation – Cancer Omics
Monday, March 1 – 3:45P-5:45P (EST)
Deep structural variance landscape mapping of renal tissue-renal cell carcinoma pairs originating from the same kidney
Dr. Tulpova Zuzana, Tel Aviv University
Poster Presentation – Technology Development
Tuesday, March 2 – 3:30P-5:30P (EST)
Identifying Polymorphic Variants at Complex Regions Using Optical Genome Mapping
Dr. Joyce Lee, Bionano Genomics
Tuesday, March 2 – 5:30P-6:30P (EST)
Hear About the Future of Genomic Analysis with Bionano’s CEO and CMO
Live interview of Dr. Erik Holmlin, CEO and Dr. Alka Chaubey, CMO of Bionano Genomics by Theral Timpson, Host, Producer and Co-Founder of Mendelspod
About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and content of the presentations identified in this press release and Bionano’s participation in the live interview conducted by Theral Timpson. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577